Plain-English translation of NCT06792162 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether combining two medications — carilizumab (a type of immune-boosting drug) and apatinib (a drug that blocks blood vessel growth to tumors) — can shrink advanced stomach cancer enough to make it possible to remove surgically. The study will enroll 20 patients with a specific type of stomach cancer that has not been treated before, and will track how well the medication works over time.
Some advanced stomach cancers cannot be surgically removed when first diagnosed, which limits treatment options. Researchers believe that this medication combination might shrink tumors enough to make surgery possible, potentially improving survival and giving patients more treatment choices.
You likely qualify if…
You likely don't qualify if…
You will receive the two medications every 21 days as an outpatient. Every 6 weeks (after every 2 medication cycles), doctors will use imaging scans to check if your tumor has shrunk enough for surgery. If it has, you may proceed to surgery; if not, you'll continue the medication. After surgery (or if surgery isn't possible), you'll continue the same medication combination for up to 2 years or until your cancer progresses. Throughout and after treatment, you'll have regular check-in visits, imaging scans every 2 months, and survival follow-up calls every 90 days for at least 2 years.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Peking University Third Hospital
Enrollment target
~20 participants
Started
April 2023
Primary completion
April 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in January 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Yanhong Yao
Department of Medical Oncology and Radiation Sickness, Peking University Third Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.